Theravance Biopharma, Inc. (TBPH)
After hours:
| Previous Close | 8.62 |
| Open | 8.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 8.56 - 8.82 |
| 52 Week Range | 7.44 - 11.71 |
| Volume | |
| Avg. Volume | 316,598 |
| Market Cap | 430.514M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Nov 05, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.20 |
PR NewswireTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the area under the curve (AUC) lung function effects in moderate-to-very-severe chronic obstructive pulmonary disease (CO
GuruFocus.comSeth Klarman's Complete Exit from Theravance Biopharma Inc
On August 31, 2024, The Baupost Group, led by renowned value investor Seth Klarman (Trades, Portfolio), executed a significant transaction by completely exiting its position in Theravance Biopharma Inc (NASDAQ:TBPH). This move has notably reduced the firm's exposure in the biotechnology sector, reflecting a strategic shift or reassessment of the stock's future potential.
